{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"Combi-TED","nct_id":"NCT04884282","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=combi-ted-nct04884282. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"COMBI-TED","arms":[{"description":"Tedopi every 3 weeks plus docetaxel every 3 weeks only for 6 cycles, then maintenance with Tedopi alone every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal.","label":"Arm A - tedopi + docetaxel","type":"EXPERIMENTAL"},{"description":"Tedopi every 3 weeks plus nivolumab 360 mg every 3 weeks for 6 cycles, then maintenance nivolumab 360 mg every 3 weeks plus Tedopi every 6 weeks until the end of year 1, then every 12 weeks until disease progression, unacceptable toxicity or patient refusal","label":"Arm B - tedopi + nivolumab","type":"EXPERIMENTAL"},{"description":"Docetaxel every 3 weeks until disease progression, unacceptable toxicity, patient refusal, or for a maximum of 6 cycles (whichever comes first).","label":"Arm C - docetaxel","type":"OTHER"}],"collaborators":[],"completion_date":{"date":"2028-09-30","type":"ESTIMATED"},"conditions":["Metastatic Non Small Cell Lung Cancer"],"enrollment":{"count":105,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Tedopi","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-06","lead_sponsor":"Fondazione Ricerca Traslazionale","official_title":"A Multicenter, Phase II, Open Label, Randomized Trial Evaluating the Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"1-year Survival Rate","timeFrame":"1 year"}],"references":[{"citation":"Landi L, Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, Borra G, Giannarelli D, Andrikou K, Mangiola D, Gori S, D'Andrea MR, Minuti G, Resuli B, Laudisi A, Vidiri A, Conti L, Cappuzzo F. Combi-TED: a new trial testing Tedopi(R) with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. Future Oncol. 2022 Dec;18(40):4457-4464. doi: 10.2217/fon-2022-0913. Epub 2023 Mar 22.","pmid":"36946237","type":"DERIVED"}],"start_date":{"date":"2021-10-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)","url":"https://clinicaltrials.gov/study/NCT04884282"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/combi-ted-nct04884282"}